A new “exploratory” report from the Institute for Clinical and Economic Review highlights the lack of information available on US payer decisions regarding formulary placement and utilization management restrictions for prescription drugs, suggesting a new area of focus in the broader push for US payer transparency.
ICER’s first annual
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?